Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250197 · ClinicalTrials.gov registry record · Phase 1
Formulation Comparison in Normal Volunteers
A Phase 1 study of Normal Volunteers, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01250197 is a Phase 1 study of Normal Volunteers that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 18 participants, below the 1,458-participant average among 4 other Normal Volunteers trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01250197, a Phase 1 study of Normal Volunteers, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.
Conditions Studied
Interventions
- DRUG AR-12286
Study Locations (1)
Arizona
- Celerion - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250197
The ClinicalTrials.gov registry entry for NCT01250197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,458-participant average among 4 other Normal Volunteers trials with a reported enrollment target (99% lower). The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Normal Volunteers appearing as the primary indexed condition, and to 1 intervention - of which AR-12286 is the first listed.
NCT01250197 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01250197 about?
NCT01250197 is a clinical study titled "Formulation Comparison in Normal Volunteers". This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.
What is the current status of trial NCT01250197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2010-12.
What conditions does trial NCT01250197 study?
This clinical trial studies the following conditions: Normal Volunteers.
What interventions are being tested in trial NCT01250197?
The interventions under investigation include: AR-12286 (DRUG).
Who is sponsoring clinical trial NCT01250197?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01250197 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Normal Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
COMPLETED · Phase 1
-
Tissue Procurement for Biomedical Research
RECRUITING
-
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.